Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Keros Therapeutics Inc KROS

Biotechnology
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or... see more

Recent & Breaking News (NDAQ:KROS)

Keros Therapeutics to Present at Upcoming Healthcare Conferences

GlobeNewswire November 22, 2022

Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions

GlobeNewswire November 7, 2022

Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047

GlobeNewswire November 3, 2022

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

GlobeNewswire November 3, 2022

Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

GlobeNewswire September 12, 2022

Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

GlobeNewswire September 6, 2022

Keros Therapeutics to Present at the American Society for Bone and Mineral Research 2022 Annual Meeting

GlobeNewswire September 6, 2022

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions

GlobeNewswire June 13, 2022

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association

GlobeNewswire June 10, 2022

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

GlobeNewswire May 18, 2022

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

GlobeNewswire May 17, 2022

Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association

GlobeNewswire May 12, 2022

Keros Therapeutics Reports First Quarter 2022 Financial Results

GlobeNewswire May 5, 2022

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire March 9, 2022

Keros Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 11, 2022

Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer

GlobeNewswire January 31, 2022

Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

GlobeNewswire December 13, 2021

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

GlobeNewswire December 13, 2021

Keros Therapeutics Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to KER-050 in China

GlobeNewswire December 13, 2021